What Novo Nordisk’s disappointing trial results mean for the obesity drug market

The long-standing edge that Novo Nordisk has held within the weight problems drug market was thrown into query Friday when the corporate reported outcomes of a carefully watched candidate that fell in need of expectations.

Novo reported that, in a late-stage research, a next-generation weight problems drug referred to as CagriSema led sufferers to lose 20% of their weight at 68 weeks when taking a look at all members — lower than the corporate’s personal projection of about 25% weight reduction. Novo’s inventory had tanked by almost 18% noon Friday.

Traders had excessive hopes for CagriSema — a mixture of semaglutide, the energetic ingredient in in style therapies Ozempic and Wegovy, and cagrilintide, a therapy that prompts amylin and calcitonin receptors. The readout will possible exacerbate considerations about Novo’s potential to observe up on the success of blockbusters Ozempic and Wegovy.